series-c-plus
Stage
2
Investors
About
Cabaletta Bio is a clinical-stage biotechnology company developing engineered T cell therapies based on its CABA® platform to treat and potentially cure patients with autoimmune diseases such as lupus, myositis, systemic sclerosis, and pemphigus vulgaris.
Explore Cabaletta Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.